References from New FDA-Approved Treg Therapy to Reduce Chronic GVHD After Allogeneic HSCT. Local targets link to admitted publications; unresolved targets remain external evidence.
No reference evidence is available for this admitted work.
References for New FDA-Approved Treg Therapy to Reduce Chronic GVHD After Allogeneic HSCT | ResearchHub - ResearchHub
